| Elizabeth A Deaton, PNP | |
|
615 Shipyard Blvd, Wilmington, NC 28412-6431 | |
| (910) 343-0145 | |
| (910) 341-5779 |
| Full Name | Elizabeth A Deaton |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Psychiatric/mental Health |
| Location | 615 Shipyard Blvd, Wilmington, North Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447254438 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth A Deaton, PNP 615 Shipyard Blvd, Wilmington, NC 28412-6431 Ph: (910) 343-0145 | Elizabeth A Deaton, PNP 615 Shipyard Blvd, Wilmington, NC 28412-6431 Ph: (910) 343-0145 |
News Archive
Congressman Chaka Fattah (D-PA) shot back today at what he called "baloney" coming from Washington Republicans: "Every step along the way these nattering nabobs of negativity have said we couldn't get it done. They said we would never move a bill out of Energy and Commerce. They said the Senate Finance Committee would never report a bill. They said the House vote would be strictly party lines and that the Senate would never let it out. Well, here we are at the finish line, and they're at it again.
Every week reporter Ankita Rao selects interesting reading from around the Web.
From a tool for treating burn victims to a technique for detecting neurodevelopmental disorders, new products and services for patients are now being developed with support from the University of Missouri's Coulter Translational Partnership Program. Today, the program announced that it is awarding funding to five teams of physicians and engineers who are working together to improve health care.
Apricus Biosciences, Inc., backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT drug delivery technology and internal pipeline through out-licensing partnerships, today announced that the Japanese Patent Office has issued a Decision to Grant a Patent for the Company's application on Femprox entitled, Compositions and Methods for Amelioration of Human Female Sexual Dysfunction.
› Verified 7 days ago